Bapineuzumab: Anti-β-amyloid monoclonal antibodies for the treatment of Alzheimers disease

Francesco Panza, Vincenza Frisardi, Bruno P. Imbimbo, Grazia Donofrio, Giuseppe Pietrarossa, Davide Seripa, Alberto Pilotto, Vincenzo Solfrizzi

Research output: Contribution to journalArticlepeer-review


In the last decade, new therapeutic approaches targeting b-amyloid (Aβ) have been discovered and developed with the hope of modifying the natural history of Alzheimer's disease (AD). The most revolutionary of these approaches consists in the removal of brain Aβ via anti-Aβ antibodies. After an active vaccine (AN1792) was discontinued in 2002 due to occurrence of meningoencephalitis in approximately 6% of patients, several other second-generation active Aβ vaccines and passive Aβ immunotherapies have been developed and are under clinical investigation with the aim of accelerating Aβ clearance from the brain of AD patients. The most advanced of these immunological approaches is bapineuzumab, which is composed of humanized anti-Aβ monoclonal antibodies that has been tested in two Phase II trials. Bapineuzumab has been shown to reduce Aβ burden in the brain of AD patients. However, its preliminary cognitive efficacy appears uncertain, particularly in ApoE ε4 carriers, and vasogenic edema may limit its clinical use. The results of four ongoing large Phase III trials on bapineuzumab will provide answers regarding whether passive anti-Aβ immunization is able to alter the course of this devastating disease.

Original languageEnglish
Pages (from-to)767-782
Number of pages16
Issue number6
Publication statusPublished - Nov 2010


  • β-amyloid
  • active immunotherapy
  • Alzheimer's disease
  • bapineuzumab
  • passive immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology


Dive into the research topics of 'Bapineuzumab: Anti-β-amyloid monoclonal antibodies for the treatment of Alzheimers disease'. Together they form a unique fingerprint.

Cite this